Skip to content
Search

Latest Stories

New study reveals how to 'measure' chronic pain using brain signals

While pain is typically a subjective experience, there is still much to discover about how pain signals are processed in the brain

New study reveals how to 'measure' chronic pain using brain signals

New research has shown that chronic pain can be objectively measured using brain signals, a report in The Conversation said.

According to the report, a team of researchers conducted a study using brain implants capable of recording neural signals over an extended period.


Their aim was to identify reliable markers of chronic pain severity in four patients as they went about their daily lives.

While pain is typically a subjective experience, there is still much to discover about how pain signals are processed in the brain.

Previous studies often relied on artificial settings, and the relationship between acute and chronic pain circuits remained unclear.

To investigate this further, the researchers surgically implanted electrodes in the brains of four patients experiencing post-stroke pain and phantom limb pain.

Neural signals were recorded in specific brain regions associated with planning, expectation, and emotion.

The patients were then asked to report their pain severity levels multiple times a day for up to six months.

Machine learning models were developed to analyze the recorded brain activity signals and predict the patients' self-reported pain intensity scores.

The findings unveiled a significant connection between low-frequency brain activity in the orbitofrontal cortex and the patients' subjective pain intensities, providing an objective measure of chronic pain.

A greater shift in low-frequency activity indicated more intense pain.

Furthermore, a comparison between chronic pain and acute pain revealed distinct brain regions involved in processing each type of pain. This experiment shed light on the differences in information processing between acute and chronic pain.

Chronic pain affects a substantial portion of the population and has a higher prevalence than conditions like diabetes, high blood pressure, or depression. It poses challenges for effective treatment and can significantly impact both physical and emotional well-being.

Improved understanding of how to measure brain activity to track pain could lead to enhanced diagnosis and the development of novel treatments, such as deep brain stimulation.

While this study offers valuable insights into using specific brain regions as objective measures of chronic pain, there is still much more to uncover.

Pain signals are likely distributed across a wider brain network, and researchers are yet to determine other brain regions that may play vital roles in reflecting subjective pain.

Additionally, it remains uncertain whether the identified signals will apply to other types of pain conditions.

Looking ahead, the researchers aim to leverage these newly discovered neural biomarkers to create personalised brain stimulation approaches for treating chronic pain disorders.

This entails developing algorithms that incorporate the identified signals to govern the timing and location of brain stimulation, similar to how a thermostat operates.

More For You

Mounjaro price rise

Eli Lilly has agreed a discounted supply deal for its weight-loss drug Mounjaro

iStock

Mounjaro’s highest dose to rise from £122 to £247.50, not £330

Highlights:

  • Eli Lilly had announced a steep price rise of up to 170% for Mounjaro.
  • A new discount deal with UK suppliers will limit the increase for patients.
  • Pharmacies will still apply a mark-up, but consumer costs are expected to rise less than initially feared.
  • NHS pricing remains unaffected due to separate arrangements.

Eli Lilly has agreed a discounted supply deal for its weight-loss drug Mounjaro, easing fears of a sharp rise in costs for UK patients. The new arrangement means that, from September, pharmacies and private services will face smaller wholesale increases than first expected, limiting the impact on consumers.

Why the price rise was announced

Earlier this month, Eli Lilly said it would raise Mounjaro’s list price by as much as 170%, which could have pushed the highest monthly dose from £122 to £330. The company argued that UK pricing needed to align more closely with higher costs in Europe and the United States.

Keep ReadingShow less
chicken-pox-istock

The Department of Health said the rollout would reduce missed days at nursery and school, cut time parents take off work, and save the NHS about £15 million a year. (Representational image: iStock)

iStock

England to introduce free chickenpox vaccine for children from 2026

CHILDREN in England will be offered a free chickenpox vaccine for the first time from January 2026, the government has announced.

GP practices will give eligible children a combined vaccine for measles, mumps, rubella and varicella (MMRV) as part of the routine childhood vaccination schedule. Around half a million children each year are expected to be protected.

Keep ReadingShow less
Naga Munchetty urges women to prioritise their health

Naga Munchetty

Naga Munchetty urges women to prioritise their health

WHEN broadcaster and journalist Naga Munchetty began speaking openly about her experiences with adenomyosis and debilitating menstrual pain, the response was overwhelming.

Emails and messages poured in from women who had endured years of dismissal, silence and shame when it came to their health. That outpouring became the driving force behind her new book, It’s Probably Nothing, which calls for women to be heard and to advocate for themselves in a medical system that has too often ignored them.

Keep ReadingShow less
London temple project for Shree Banke Bihari launched

London temple project for Shree Banke Bihari launched

Mahesh Liloriya

The Shree Kunj Bihari Vrindavan (UK) Temple has officially launched its project to establish a grand home for Shree Banke Bihari in London.

The inaugural event, held in Harrow from 4 pm, featured devotional chants, the Deep Pragtya ceremony, and a presentation outlining the temple’s vision. Speaking at the gathering, Shalini Bhargava described the planned temple as “a spiritual home promoting bhakti, unity and seva for generations to come.”

Keep ReadingShow less
Dickie and Watt

Dickie and Watt launched BrewDog at the age of 24

Getty Images

BrewDog co-founder Martin Dickie leaves after 17 years as James Watt steps back

Highlights:

  • Martin Dickie has announced his departure from BrewDog and the alcohol industry.
  • He co-founded the Ellon-based brewer with James Watt in 2007.
  • Dickie cited family time and personal reasons for his exit.
  • His departure follows recent bar closures as part of a company restructuring.
  • BrewDog confirmed no further leadership changes will follow.

BrewDog co-founder Martin Dickie has announced he is leaving the Scottish brewer and the wider alcohol industry for “personal reasons.” Dickie, who founded the Ellon-based business with James Watt in 2007, said he wanted to spend more time with his family after more than two decades in brewing and distilling.

Early beginnings

Dickie and Watt launched BrewDog at the age of 24, starting from a garage in Fraserburgh and selling hand-filled bottles from a van at local markets. The company grew rapidly to become one of the UK’s best-known craft brewers.

Keep ReadingShow less